BRPI0315188B8 - composto e composição farmacêutica - Google Patents

composto e composição farmacêutica

Info

Publication number
BRPI0315188B8
BRPI0315188B8 BRPI0315188A BR0315188A BRPI0315188B8 BR PI0315188 B8 BRPI0315188 B8 BR PI0315188B8 BR PI0315188 A BRPI0315188 A BR PI0315188A BR 0315188 A BR0315188 A BR 0315188A BR PI0315188 B8 BRPI0315188 B8 BR PI0315188B8
Authority
BR
Brazil
Prior art keywords
compound
alkyl
formula
pharmaceutical composition
amino
Prior art date
Application number
BRPI0315188A
Other languages
English (en)
Other versions
BRPI0315188B1 (pt
BR0315188A (pt
Inventor
Toda Ayako
Ohki Hidenori
Misumi Keiji
Itoh Kenji
Satoh Kenji
Kawabata Kohji
Ohgaki Masaru
Inoue Satoshi
Okuda Shinya
Yamanaka Toshio
Original Assignee
Astellas Pharma Inc
Wakunaga Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002952355A external-priority patent/AU2002952355A0/en
Priority claimed from AU2003904813A external-priority patent/AU2003904813A0/en
Application filed by Astellas Pharma Inc, Wakunaga Pharma Co Ltd filed Critical Astellas Pharma Inc
Publication of BR0315188A publication Critical patent/BR0315188A/pt
Publication of BRPI0315188B1 publication Critical patent/BRPI0315188B1/pt
Publication of BRPI0315188B8 publication Critical patent/BRPI0315188B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

"compostos de cefem". a invenção presente refere-se a um composto da fórmula [i]: onde r^ 1^ é alquila inferior, hidroxi-alquila (inferior) ou halo-alquila (inferior), e r^ 2^ é hidrogênio ou grupo protetor amino, ou r^ 1^ e r^ 2^ estão ligados entre si e formam alquileno inferior ou alquenileno inferior; r^ 3^ é hidrogênio ou alquila inferior; r^ 4^ é r^ 5^ é carboxi ou carboxi protegido; e r^ 6^ é amino ou amino protegido, ou um sal farmaceuticamente aceitável do mesmo, um processo para preparar um composto da fórmula [i], e uma composição farmacêutica compreendendo um composto da fórmula [i] em mistura com um condutor farmaceuticamente aceitável.
BRPI0315188A 2002-10-30 2003-10-27 composto e composição farmacêutica BRPI0315188B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952355A AU2002952355A0 (en) 2002-10-30 2002-10-30 Cephem compounds
AU2003904813A AU2003904813A0 (en) 2003-09-04 Cephem Compounds
PCT/JP2003/013684 WO2004039814A1 (en) 2002-10-30 2003-10-27 Cephem compounds

Publications (3)

Publication Number Publication Date
BR0315188A BR0315188A (pt) 2005-09-06
BRPI0315188B1 BRPI0315188B1 (pt) 2017-04-25
BRPI0315188B8 true BRPI0315188B8 (pt) 2021-05-25

Family

ID=32231625

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0315188A BRPI0315188B8 (pt) 2002-10-30 2003-10-27 composto e composição farmacêutica

Country Status (20)

Country Link
US (2) US7129232B2 (pt)
EP (1) EP1556389B9 (pt)
JP (1) JP4448821B2 (pt)
KR (1) KR101023035B1 (pt)
AR (1) AR041729A1 (pt)
AT (1) ATE368042T1 (pt)
BE (1) BE2016C002I2 (pt)
BR (1) BRPI0315188B8 (pt)
CA (1) CA2504730C (pt)
DE (1) DE60315178T3 (pt)
DK (1) DK1556389T6 (pt)
ES (1) ES2290498T7 (pt)
FR (1) FR16C0004I2 (pt)
HK (1) HK1086566A1 (pt)
HU (1) HUS1600008I1 (pt)
LU (1) LU92943I2 (pt)
NL (1) NL300793I2 (pt)
PT (1) PT1556389E (pt)
TW (1) TWI319403B (pt)
WO (1) WO2004039814A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60209341T2 (de) * 2001-05-01 2006-08-03 Astellas Pharma Inc. Cephem-verbindungen
ATE368042T1 (de) * 2002-10-30 2007-08-15 Astellas Pharma Inc Cephemverbindungen
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
AR045768A1 (es) * 2003-09-18 2005-11-09 Fujisawa Pharmaceutical Co Compuestos de cefem y sus sales farmaceuticamente aceptables
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
EP1994035A1 (en) * 2006-03-16 2008-11-26 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
ITFE20060029A1 (it) * 2006-10-17 2008-04-18 Gruppo Kemon Spa Intermedi eterociclici primari per la colorazione ossidativa dei capelli a struttura pirazolica
CA2702257C (en) 2007-10-09 2016-07-12 Sopharmia, Inc. Broad spectrum beta-lactamase inhibitors
KR101960555B1 (ko) 2011-05-13 2019-03-20 어레이 바이오파마 인크. Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물
EA028342B1 (ru) 2011-09-09 2017-11-30 Мерк Шарп И Доум Корп. Способы лечения пневмонии
EP2628730B1 (en) * 2012-02-16 2017-12-06 Noxell Corporation Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
BR112015006868B1 (pt) 2012-09-27 2021-11-30 Merck Sharp & Dohme Corp Composição farmacêutica de tazobactam-arginina cristalina e composto beta-lactâmico, seu uso, método para fazer uma composição farmacêutica e uso de tazobactam-arginina cristalina e de composto beta-lactâmico
US9006421B2 (en) 2013-03-14 2015-04-14 Cubist Pharmaceuticals, Inc. Cephalosporin compositions and methods of manufacture
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274991A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
AU2014227660B2 (en) 2013-03-15 2014-11-06 Merck Sharp & Dohme Llc Ceftolozane antibiotic compositions
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) * 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US20160228448A1 (en) * 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Solid Forms of Ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
MA40434B1 (fr) 2014-05-15 2019-09-30 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka
CN106795175A (zh) 2014-08-15 2017-05-31 默沙东公司 头孢菌素化合物的合成
US10221196B2 (en) 2014-08-15 2019-03-05 Merck Sharp & Dohme Corp. Intermediates in the synthesis of cephalosporin compounds
US10000510B2 (en) 2014-08-18 2018-06-19 Merck Sharp & Dohme Corp. Salt forms of ceftolozane
US10059680B2 (en) 2014-12-18 2018-08-28 Merck Sharp & Dohme Corp. Thiadiazolyl-oximinoacetic acid derivative compounds
US10035774B2 (en) 2014-12-18 2018-07-31 Merck Sharp & Dohme Corp. Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds
US20160176897A1 (en) 2014-12-23 2016-06-23 Merck Sharp & Dohme Corp. 7-aminocephem derivative compounds
WO2016109259A2 (en) * 2014-12-30 2016-07-07 Merck Sharp & Dohme Corp. Synthesis of cephalosporin compounds
US10351533B2 (en) 2015-06-29 2019-07-16 Sandoz Ag Process for the preparation of carbamoylamino pyrazole derivatives
EP3347362B1 (en) 2015-09-08 2019-10-23 Sandoz AG Process for preparing ceftolozane from 7-aminocephalosporanic acid (7-aca)
AU2016367284C1 (en) 2015-12-10 2018-09-20 Naeja-Rgm Pharmaceuticals Ulc Cephem compounds, their production and use
US11542279B2 (en) 2016-06-06 2023-01-03 Merck Sharp & Dohme Llc Solid forms of ceftolozane and processes for preparing
CN107586305A (zh) * 2017-06-23 2018-01-16 浙江惠迪森药业有限公司 一种β‑内酰胺类化合物羧基及羟基保护基脱除方法
WO2019145784A2 (en) * 2018-01-26 2019-08-01 Legochem Biosciences, Inc. Combination therapies for multi-drug resistant pathogens
CN109369535A (zh) * 2018-11-07 2019-02-22 浙江东邦药业有限公司 一种氨基甲酰氨基吡唑衍生化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78245B (pt) * 1980-09-12 1984-09-26 Ciba Geigy Ag
US5194432A (en) 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
CA1293719C (en) * 1986-09-22 1991-12-31 Takao Takaya Cephem compounds and processes for preparation thereof
US5663163A (en) * 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
US5210080A (en) * 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
IE63094B1 (en) * 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
US5173485A (en) * 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
GB8905301D0 (en) * 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
US5215982A (en) * 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
KR910015587A (ko) * 1990-02-27 1991-09-30 후지사와 토모키치로 세펨 화합물
GB9023479D0 (en) * 1990-10-29 1990-12-12 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤
AUPN955596A0 (en) 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
TW526202B (en) * 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
DE60209341T2 (de) * 2001-05-01 2006-08-03 Astellas Pharma Inc. Cephem-verbindungen
ATE368042T1 (de) * 2002-10-30 2007-08-15 Astellas Pharma Inc Cephemverbindungen
AU2003902380A0 (en) * 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
AR045768A1 (es) * 2003-09-18 2005-11-09 Fujisawa Pharmaceutical Co Compuestos de cefem y sus sales farmaceuticamente aceptables

Also Published As

Publication number Publication date
HUS1600008I1 (hu) 2016-03-29
NL300793I1 (pt) 2016-03-15
CA2504730C (en) 2011-04-12
US20070037786A1 (en) 2007-02-15
KR20050084897A (ko) 2005-08-29
DE60315178D1 (de) 2007-09-06
BRPI0315188B1 (pt) 2017-04-25
BR0315188A (pt) 2005-09-06
HK1086566A1 (en) 2006-09-22
LU92943I2 (fr) 2016-03-14
KR101023035B1 (ko) 2011-03-24
AR041729A1 (es) 2005-05-26
NL300793I2 (pt) 2016-03-15
DK1556389T3 (da) 2007-11-26
US7129232B2 (en) 2006-10-31
WO2004039814A1 (en) 2004-05-13
ES2290498T3 (es) 2008-02-16
ATE368042T1 (de) 2007-08-15
DE60315178T2 (de) 2008-04-30
ES2290498T7 (es) 2015-07-10
FR16C0004I2 (fr) 2017-01-06
EP1556389B1 (en) 2007-07-25
DE60315178T3 (de) 2015-06-18
DK1556389T6 (da) 2015-05-11
TW200410977A (en) 2004-07-01
TWI319403B (en) 2010-01-11
EP1556389B9 (en) 2015-09-09
US20040132994A1 (en) 2004-07-08
PT1556389E (pt) 2007-11-08
EP1556389B3 (en) 2015-04-01
CA2504730A1 (en) 2004-05-13
BE2016C002I2 (pt) 2023-03-07
FR16C0004I1 (fr) 2016-03-25
JP2006506459A (ja) 2006-02-23
EP1556389A1 (en) 2005-07-27
JP4448821B2 (ja) 2010-04-14

Similar Documents

Publication Publication Date Title
BRPI0315188B8 (pt) composto e composição farmacêutica
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
BR0209452A (pt) Composto de cefem, processo para sua preparação, composição farmacêutica e uso do composto
TW368500B (en) 1-Benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
CA2304713A1 (en) Biphenyl-5-alkanoic acid derivatives and use thereof
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
AU5249898A (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
BR0013248A (pt) Inibidores da adesão celular
HUT65351A (en) Process for preparing ethanolamine derivatives haring sympathominetic and anti-pollakiuria activity and pharmaceutical compositions containing them as active agent
HUP0203184A2 (hu) Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AR045768A1 (es) Compuestos de cefem y sus sales farmaceuticamente aceptables
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
BR0312798A (pt) Derivados de isotiazol úteis como agentes anticancerìgenos
MXPA02004555A (es) Azetidinas de [(indol-??3-il)cicloalquil]-3-substituidas para el tratamiento de padecimientos del sistema nervioso central.
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
IL181888A0 (en) Aminoalcohol derivatives and pharmaceutical compositions containing the same
TW200500369A (en) Cephem compounds
ATE161178T1 (de) Pyrazolpyridine für die behandlung der anämie
BRPI0416746A (pt) processo de sìntese do perindopril e de seus sais farmaceuticamente aceitáveis
BR0006299A (pt) Derivados da 4-oxo-2-ureìdo-1,4,5,6-tetra-hidro-pirimidina
DE602004023510D1 (de) Verzweigte carbonsäureverbindung und deren verwendung
IL111725A0 (en) 3'-aziridino-anthracycline derivatives, their preparation and pharmaceutical compositions containing them
WO2002074777A3 (en) Pyranocoumarin compounds as a novel pharmacophore with anti-tb activity

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF